Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012–2013

Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)–diagnosed persons in care. Methods. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 63; no. 7; pp. 976 - 983
Main Authors Crepaz, Nicole, Tang, Tian, Marks, Gary, Mugavero, Michael J., Espinoza, Lorena, Hall, H. Irene
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)–diagnosed persons in care. Methods. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012–2013. Results. Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012–2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Conclusions. Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression.
AbstractList Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care. Methods. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013. Results. Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Conclusions. Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression.
We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013. Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression.
BACKGROUNDWe examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care.METHODSUsing data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013.RESULTSOf 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential.CONCLUSIONSTwo-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression.
Author Marks, Gary
Mugavero, Michael J.
Crepaz, Nicole
Espinoza, Lorena
Tang, Tian
Hall, H. Irene
Author_xml – sequence: 1
  givenname: Nicole
  surname: Crepaz
  fullname: Crepaz, Nicole
– sequence: 2
  givenname: Tian
  surname: Tang
  fullname: Tang, Tian
– sequence: 3
  givenname: Gary
  surname: Marks
  fullname: Marks, Gary
– sequence: 4
  givenname: Michael J.
  surname: Mugavero
  fullname: Mugavero, Michael J.
– sequence: 5
  givenname: Lorena
  surname: Espinoza
  fullname: Espinoza, Lorena
– sequence: 6
  givenname: H. Irene
  surname: Hall
  fullname: Hall, H. Irene
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27358354$$D View this record in MEDLINE/PubMed
BookMark eNqNkk1v1DAQhi1URNuFC3eQJS4IEfDEduxwQKpaoCtVoqIfHC3H8W69ZO3FdkDc-h_4h_wSvEopHycO1ljzPn41M559tOODtwg9BPICSEtfGteX85WBvIP2gFNRNbyFnXInXFZMUrmL9lNaEQIgCb-HdmtBuaSc7aHrozHqbrD40kU94LNxs4k2JRc81r7H51H7tHZT4oNLn_BpyNZnV9iDdfBLfGpjCj7hjy5f4SOnlz4k2-Pj-SWe-4U1ubx8hS-8yyV7lnW26TmuCdQ_rr-XQO-juws9JPvgJs7Qxds354fH1cn7d_PDg5PKsAZyJaBhdWOZ7CXXtqO0IaSDVogFCEEoSAqCGy1MxwihnWam67nujRXAhNGEztDryXczdmtbBJ9Lw2oT3VrHbypop_5WvLtSy_BFcVJDQ7cGT28MYvg82pRVmYuxw6C9DWNSIGvRAqsp_Q8UWkZLnaygT_5BV2GMvkxia8gokKb0NkPPJsrEkFK0i9u6gajtDqiyA2ragQI__rPTW_TXpxfg0QSsUg7xt95QUReA_gQwgbjj
CitedBy_id crossref_primary_10_1080_08964289_2020_1809336
crossref_primary_10_1097_QAI_0000000000002360
crossref_primary_10_1080_09540121_2018_1545989
crossref_primary_10_1093_ofid_ofae087
crossref_primary_10_1155_2020_9247451
crossref_primary_10_1177_22799036231182031
crossref_primary_10_7448_IAS_19_1_21348
crossref_primary_10_1007_s40615_021_01227_w
crossref_primary_10_1093_infdis_jiab021
crossref_primary_10_1093_cid_ciz276
crossref_primary_10_1080_09540121_2017_1417535
crossref_primary_10_1097_QAI_0000000000003178
crossref_primary_10_1002_jia2_26162
crossref_primary_10_1089_apc_2021_0137
crossref_primary_10_1089_apc_2018_0004
crossref_primary_10_1097_QAI_0000000000003045
crossref_primary_10_1016_j_drugalcdep_2019_107670
crossref_primary_10_1007_s10903_018_0753_2
crossref_primary_10_1093_cid_cix940
crossref_primary_10_1016_j_cct_2020_106097
crossref_primary_10_1080_09540121_2020_1771264
crossref_primary_10_1093_ofid_ofz203
crossref_primary_10_1097_QAD_0000000000001660
crossref_primary_10_1007_s10461_019_02734_y
crossref_primary_10_1007_s10461_019_02650_1
crossref_primary_10_1080_09540121_2020_1826396
crossref_primary_10_1093_pm_pnx057
crossref_primary_10_1097_QAI_0000000000001779
crossref_primary_10_1186_s12981_024_00626_3
crossref_primary_10_1007_s10461_019_02644_z
crossref_primary_10_3390_ijerph18158031
crossref_primary_10_1177_09564624211002403
crossref_primary_10_3389_fgene_2018_00720
crossref_primary_10_1097_OLQ_0000000000000776
crossref_primary_10_1136_bmjopen_2017_018533
crossref_primary_10_1016_S0140_6736_21_00396_2
crossref_primary_10_1007_s10461_019_02474_z
crossref_primary_10_1007_s10461_021_03157_4
crossref_primary_10_1371_journal_pone_0244376
crossref_primary_10_1186_s12981_021_00400_9
crossref_primary_10_1007_s10461_024_04275_5
crossref_primary_10_1007_s10461_021_03342_5
crossref_primary_10_1097_QAI_0000000000002056
crossref_primary_10_1007_s11606_024_08847_y
crossref_primary_10_3390_ijerph18084170
crossref_primary_10_1177_0033354918772057
crossref_primary_10_1136_sextrans_2017_053178
crossref_primary_10_1093_cid_cix212
crossref_primary_10_1097_QAI_0000000000001877
crossref_primary_10_1097_QAI_0000000000002848
crossref_primary_10_1007_s10865_020_00186_7
crossref_primary_10_1080_13607863_2022_2084504
crossref_primary_10_1093_tbm_ibaa109
crossref_primary_10_1007_s10461_019_02627_0
crossref_primary_10_1016_j_ptdy_2020_03_017
crossref_primary_10_1080_09540121_2022_2080800
crossref_primary_10_1097_MD_0000000000026285
crossref_primary_10_1080_25787489_2020_1735816
crossref_primary_10_1007_s10461_020_03153_0
crossref_primary_10_1007_s10461_019_02578_6
crossref_primary_10_1007_s10461_020_02811_7
crossref_primary_10_1007_s10461_022_03694_6
crossref_primary_10_1177_2150132720984429
crossref_primary_10_1177_09564624211046516
crossref_primary_10_1186_s12879_017_2550_2
crossref_primary_10_1007_s10461_020_02778_5
crossref_primary_10_1016_j_alcohol_2021_04_003
crossref_primary_10_1089_apc_2021_0067
crossref_primary_10_1007_s11121_019_01013_5
crossref_primary_10_1097_QAI_0000000000002277
crossref_primary_10_1097_QAI_0000000000003128
crossref_primary_10_1097_QAI_0000000000003129
crossref_primary_10_1001_jamainternmed_2017_2158
crossref_primary_10_1186_s12889_020_8442_1
crossref_primary_10_1080_08870446_2022_2122462
crossref_primary_10_1007_s10461_019_02399_7
crossref_primary_10_1097_QAI_0000000000002308
crossref_primary_10_1136_bmjopen_2023_077676
crossref_primary_10_1097_QAD_0000000000001597
crossref_primary_10_1001_jama_2018_8431
crossref_primary_10_1097_QAI_0000000000003237
crossref_primary_10_1111_jrh_12384
crossref_primary_10_1186_s12889_020_10088_7
crossref_primary_10_1080_10826084_2021_1884722
crossref_primary_10_1080_09540121_2023_2206096
crossref_primary_10_1080_09540121_2018_1510099
crossref_primary_10_1097_QAD_0000000000001914
crossref_primary_10_1097_QAI_0000000000002933
crossref_primary_10_15585_mmwr_mm6704a2
crossref_primary_10_1177_2325958219826612
crossref_primary_10_1097_QAD_0000000000001921
crossref_primary_10_1097_QAD_0000000000002579
crossref_primary_10_1097_QAD_0000000000002612
crossref_primary_10_1007_s10461_020_02803_7
crossref_primary_10_1007_s10461_022_03958_1
crossref_primary_10_1371_journal_pmed_1002667
crossref_primary_10_1097_QAI_0000000000002138
crossref_primary_10_1089_apc_2020_0074
crossref_primary_10_1097_QAI_0000000000002019
Cites_doi 10.1056/NEJMoa1105243
10.1177/2325957415613442
10.1001/jamainternmed.2015.4095
10.1097/QAD.0000000000000108
10.1093/cid/cir526
10.7326/0003-4819-157-5-201209040-00005
10.1086/599313
10.1371/journal.pone.0029679
10.1097/QAD.0000000000000057
10.1097/QAI.0b013e3182945bc7
10.1097/QAI.0000000000001036
10.1001/jama.2014.7999
10.1097/QAD.0000000000000640
10.1097/QAD.0000000000000879
10.1056/NEJM200003303421303
10.1093/cid/ciu722
ContentType Journal Article
Copyright Copyright © 2016 Oxford University Press on behalf of the Infectious Diseases Society of America
Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Copyright Oxford University Press, UK Oct 1, 2016
Copyright_xml – notice: Copyright © 2016 Oxford University Press on behalf of the Infectious Diseases Society of America
– notice: Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
– notice: Copyright Oxford University Press, UK Oct 1, 2016
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7T2
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
7X8
7U2
5PM
DOI 10.1093/cid/ciw418
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Safety Science and Risk
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Safety Science Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
Safety Science and Risk
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE
MEDLINE - Academic
Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1537-6591
EndPage 983
ExternalDocumentID 4198442751
10_1093_cid_ciw418
27358354
26372835
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
Feature
GeographicLocations United States--US
USA
GeographicLocations_xml – name: United States--US
– name: USA
GrantInformation_xml – fundername: Intramural CDC HHS
  grantid: CC999999
GroupedDBID ---
..I
.2P
.I3
.ZR
08P
0R~
1KJ
1TH
29B
2AX
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
6J9
70D
AABJS
AABMN
AABZA
AACGO
AACZT
AAESY
AAIYJ
AAJKP
AAJQQ
AAMVS
AANCE
AANRK
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AAUQX
AAVAP
ABBHK
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABPLY
ABPTD
ABQLI
ABSAR
ABTLG
ABWST
ABXSQ
ABZBJ
ACGFO
ACGFS
ACIMA
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEIU
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADULT
ADVEK
ADYVW
ADZLD
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AIMBJ
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQKUS
AQVQM
ASMCH
AWCFO
AXUDD
AZQFJ
BAWUL
BAYMD
BCRHZ
BEYMZ
BGYMP
BHONS
BTRTY
BVRKM
BYORX
C45
CASEJ
CDBKE
CS3
CZ4
DAKXR
DCCCD
DIK
DILTD
DNJUQ
DOOOF
DPORF
DPPUQ
DU5
DWIUU
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
ESX
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H5~
HAR
HW0
HZ~
IOX
J21
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KAQDR
KBUDW
KOP
KSI
KSN
L7B
M49
MHKGH
MJL
ML0
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O9-
OAUYM
OAWHX
OCZFY
ODMLO
ODZKP
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TR2
W8F
X7H
YAYTL
YKOAZ
YXANX
ZA5
~91
~S-
AARHZ
AAUAY
ABNHQ
ABQNK
ABXVV
ADACV
ADQBN
ATGXG
CGR
CUY
CVF
ECM
EIF
H13
IPSME
NPM
AASNB
AAYXX
CITATION
7QL
7T2
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
7X8
7U2
5PM
ID FETCH-LOGICAL-c461t-716426e48d85aeb33600b1977f17703183175ca7cb4003ba4cbd5adce7147ca03
ISSN 1058-4838
IngestDate Tue Sep 17 21:17:12 EDT 2024
Fri Oct 25 06:25:56 EDT 2024
Fri Oct 25 07:37:01 EDT 2024
Thu Oct 10 18:48:10 EDT 2024
Thu Sep 12 19:34:10 EDT 2024
Wed Oct 16 01:00:00 EDT 2024
Fri Feb 02 07:29:58 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords HIV-diagnosed persons
disparity
durable viral suppression
viral burden
HIV transmission risk
Language English
License Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c461t-716426e48d85aeb33600b1977f17703183175ca7cb4003ba4cbd5adce7147ca03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/cid/article-pdf/63/7/976/7081320/ciw418.pdf
PMID 27358354
PQID 1824310618
PQPubID 48300
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5021630
proquest_miscellaneous_1827914233
proquest_miscellaneous_1819430034
proquest_journals_1824310618
crossref_primary_10_1093_cid_ciw418
pubmed_primary_27358354
jstor_primary_26372835
PublicationCentury 2000
PublicationDate 2016-10-01
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Oxford
PublicationTitle Clinical infectious diseases
PublicationTitleAlternate Clin Infect Dis
PublicationYear 2016
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References 25225233 - Clin Infect Dis. 2015 Jan 1;60(1):117-25
26322677 - JAMA Intern Med. 2015 Oct;175(10):1650-9
26527218 - J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14 Suppl 1:S3-S34
25038358 - JAMA. 2014 Jul 23-30;312(4):390-409
10738050 - N Engl J Med. 2000 Mar 30;342(13):921-9
25768835 - AIDS. 2015 May 15;29(8):947-54
24983541 - AIDS. 2014 Mar 13;28(5):633-56
26372483 - AIDS. 2015 Nov 28;29(18):2371-83
22944874 - Ann Intern Med. 2012 Sep 4;157(5):325-35
21890751 - Clin Infect Dis. 2011 Nov;53(9):927-35
22291892 - PLoS One. 2012;7(1):e29679
25426654 - MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1113-7
27105049 - J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):205-12
19476437 - J Infect Dis. 2009 Jul 1;200(1):79-87
23572013 - J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):299-306
24056066 - AIDS. 2014 Jan 28;28(3):407-15
21767103 - N Engl J Med. 2011 Aug 11;365(6):493-505
Centers for Disease Control and Prevention (2016091209330666000_63.7.976.12) 2014; 63
2016091209330666000_63.7.976.18
2016091209330666000_63.7.976.19
2016091209330666000_63.7.976.16
2016091209330666000_63.7.976.17
2016091209330666000_63.7.976.2
2016091209330666000_63.7.976.14
2016091209330666000_63.7.976.1
2016091209330666000_63.7.976.15
2016091209330666000_63.7.976.23
2016091209330666000_63.7.976.13
2016091209330666000_63.7.976.10
2016091209330666000_63.7.976.21
2016091209330666000_63.7.976.11
2016091209330666000_63.7.976.22
2016091209330666000_63.7.976.20
2016091209330666000_63.7.976.9
2016091209330666000_63.7.976.8
2016091209330666000_63.7.976.7
2016091209330666000_63.7.976.6
2016091209330666000_63.7.976.5
2016091209330666000_63.7.976.4
2016091209330666000_63.7.976.3
References_xml – ident: 2016091209330666000_63.7.976.1
– ident: 2016091209330666000_63.7.976.2
– ident: 2016091209330666000_63.7.976.3
  doi: 10.1056/NEJMoa1105243
– ident: 2016091209330666000_63.7.976.18
  doi: 10.1177/2325957415613442
– ident: 2016091209330666000_63.7.976.22
  doi: 10.1001/jamainternmed.2015.4095
– ident: 2016091209330666000_63.7.976.16
  doi: 10.1097/QAD.0000000000000108
– ident: 2016091209330666000_63.7.976.4
  doi: 10.1093/cid/cir526
– volume: 63
  start-page: 1
  year: 2014
  ident: 2016091209330666000_63.7.976.12
  article-title: Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011
  publication-title: MMWR Morb Mortal Wkly Rep
  contributor:
    fullname: Centers for Disease Control and Prevention
– ident: 2016091209330666000_63.7.976.9
  doi: 10.7326/0003-4819-157-5-201209040-00005
– ident: 2016091209330666000_63.7.976.6
  doi: 10.1086/599313
– ident: 2016091209330666000_63.7.976.14
  doi: 10.1371/journal.pone.0029679
– ident: 2016091209330666000_63.7.976.17
  doi: 10.1097/QAD.0000000000000057
– ident: 2016091209330666000_63.7.976.10
  doi: 10.1097/QAI.0b013e3182945bc7
– ident: 2016091209330666000_63.7.976.11
– ident: 2016091209330666000_63.7.976.13
  doi: 10.1097/QAI.0000000000001036
– ident: 2016091209330666000_63.7.976.19
  doi: 10.1001/jama.2014.7999
– ident: 2016091209330666000_63.7.976.15
  doi: 10.1097/QAD.0000000000000640
– ident: 2016091209330666000_63.7.976.20
  doi: 10.1097/QAD.0000000000000879
– ident: 2016091209330666000_63.7.976.5
  doi: 10.1056/NEJM200003303421303
– ident: 2016091209330666000_63.7.976.7
– ident: 2016091209330666000_63.7.976.21
– ident: 2016091209330666000_63.7.976.23
– ident: 2016091209330666000_63.7.976.8
  doi: 10.1093/cid/ciu722
SSID ssj0011805
Score 2.5652375
Snippet Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus...
We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed...
BACKGROUNDWe examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus...
SourceID pubmedcentral
proquest
crossref
pubmed
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 976
SubjectTerms Adolescent
Adult
Anti-HIV Agents - therapeutic use
Disease transmission
Female
HIV
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Infections - transmission
HIV Infections - virology
HIV-1
HIV/AIDS
Human immunodeficiency virus
Humans
Lentivirus
Male
Medical diagnosis
Middle Aged
Retroviridae
Risk
Risk factors
Sustained Virologic Response
United States - epidemiology
Viral Load
Young Adult
Title Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012–2013
URI https://www.jstor.org/stable/26372835
https://www.ncbi.nlm.nih.gov/pubmed/27358354
https://www.proquest.com/docview/1824310618
https://search.proquest.com/docview/1819430034
https://search.proquest.com/docview/1827914233
https://pubmed.ncbi.nlm.nih.gov/PMC5021630
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELWWIiEuiK9CoCAjOBIax46TcEMtaAsqqtAW9RbZ3qTdA9lqmwipB678bWZsx5uFgoBLtIqdZOX3PDO2n8eEvFBSg9MpoacZwWNRSBXrotHxvBTKzBvwSHZC__CjnB6L9yfZyWTyfaRa6jv9ylxeua_kf1CFe4Ar7pL9B2TDS-EG_AZ84QoIw_WvMN7vV3bn0-cFbrPHAzqdqtUJjK0bAhjtjU8oIT9adigOQlTsGUNHNtxGCWx3BsbPiu4gAJ3CkPDAi7Ss8GMjMEVQwJ-n0EZuf2dIdDBsshwEXv3FsP4TAve9Fbi_y0DBwKqZn7aejdiK24jcvL0aaZX7UwU4LUeSf7-y5acumAwiOPA8g7nNY5m587oGe-wNnuNdPjKupTsp5hej7xJiGQuyWXwVzqCP8D__YssgUstwnmvt-oIgcSi6Rq6nYLFQG7h_8CEsR7EiyYbctiXfhU_tug9hLmn_6EZg47StV41afhbfjqKZ2W1yyw9D6BvHqTtkUrd3yY1DL7S4R755alFLLTqiFgVq0TG1KFKLBmpRSy3qqUWRWjRQiwK1aKDWa-qIRR2xXtJAq_vk-N3b2d409kd1xEZI1sU46k5lLYp5kalacw5xtGYwtmhYnlu_AWGqUbnR4DO4VsLoeaagDXImcqMSvk222mVbPyS0Zqws6lolZdoIMddKpkVi8lpmDUedVkSeD-1cnbuMLJVTUvAKj6F2wERk20IQqqSS55hbMCI7AyaV78oXFQyyIZCG0BaeexaKoRlx9Uy1NXQYqMPwqIKEiz_VAfYwGKHwiDxwMK__gOdJRPINAoQKmOh9s6RdnNmE7xkE4pInj377zsfk5rp_7ZCtbtXXTyBY7vRTS-QfPAXBDA
link.rule.ids 230,315,783,787,888,27938,27939
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Durable+Viral+Suppression+and+Transmission+Risk+Potential+Among+Persons+With+Diagnosed+HIV+Infection%3A+United+States%2C+2012-2013&rft.jtitle=Clinical+infectious+diseases&rft.au=Crepaz%2C+Nicole&rft.au=Tang%2C+Tian&rft.au=Marks%2C+Gary&rft.au=Mugavero%2C+Michael+J&rft.date=2016-10-01&rft.eissn=1537-6591&rft.volume=63&rft.issue=7&rft.spage=976&rft_id=info:doi/10.1093%2Fcid%2Fciw418&rft_id=info%3Apmid%2F27358354&rft.externalDocID=27358354
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon